Association of High LDH and Low Glucose Levels in Pleural Space with HER2 Expression in Non-Small Cell Lung Cancer

Ziaian, Bizhan; Saberi, Ali; Ghayyoumi, Mohammad Ali; Safaei, Akbar; Ghaderi, Abbas; Mojtahedi, Zahra

doi:10.7314/apjcp.2014.15.4.1617

Cited by 10 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, it has been described for a long time that elevated levels of LDH are a predictor of poor prognosis in malignant pleural effusion (MPE), very likely reflecting a higher degree of necrosis in the pleural cavity (96). Recently, it has been shown for the first time a significant association between high LDH, low pleural glucose levels and overexpression of HER-2 in lung cancer (97). This relation allowed to hypothesize the possible use of low pleural glucose and high LDH levels as a screening tool for finding HER2-positive cases of lung cancer (97).…”

Section: Ldh As Diagnostic Marker Prognostic Factor and Predictive Mmentioning

confidence: 99%

Lactic dehydrogenase and cancer an overview

Gallo¹,

Sapio²,

Spina

et al. 2015

Front Biosci

View full text Add to dashboard Cite

Despite the intense scientific efforts made, there are still many tumors that are difficult to treat and the percentage of patient survival in the long-term is still too low. Thus, new approaches to the treatment of cancer are needed. Cancer is a highly heterogeneous and complex disease, whose development requires a reorganization of cell metabolism. Most tumor cells downregulate mitochondrial oxidative phosphorylation and increase the rate of glucose consumption and lactate release, independently of oxygen availability (Warburg effect). This metabolic rewiring is largely believed to favour tumor growth and survival, although the underlying molecular mechanisms are not completely understood. Importantly, the correlation between the aerobic glycolysis and cancer is widely regarded as a useful biochemical basis for the development of novel anticancer strategies. Among the enzymes involved in glycolysis, lactate dehydrogenase (LDH) is emerging as a very attractive target for possible pharmacological approaches in cancer therapy. This review addresses the state of the art and the perspectives concerning LDH both as a useful diagnostic marker and a relevant molecular target in cancer therapy and management.

show abstract

Section: Ldh As Diagnostic Marker Prognostic Factor and Predictive Mmentioning

confidence: 99%

Lactic dehydrogenase and cancer an overview

Gallo¹,

Sapio²,

Spina

et al. 2015

Front Biosci

View full text Add to dashboard Cite

show abstract

“…Markers which have been widely used for diagnosing lung cancer include CEA (Yang et al, 2014), Cyfra21-1 (Tomita et al, 2010), NES (Chu et al, 2011), LDH (Ziaian et al, 2014), CRP (Onitilo et al, 2012) and other indexes. However, single marker of lung cancer shows low diagnostic specificity and sensitivity, having poor value for the diagnosis of lung cancer (Leidinger et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

Prediction of Lung Cancer Based on Serum Biomarkers by Gene Expression Programming Methods

Chen²,

Cui³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

In diagnosis of lung cancer, rapid distinction between small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) tumors is very important. Serum markers, including lactate dehydrogenase (LDH), C-reactive protein (CRP), carcino-embryonic antigen (CEA), neurone specific enolase (NSE) and Cyfra21-1, are reported to reflect lung cancer characteristics. In this study classification of lung tumors was made based on biomarkers (measured in 120 NSCLC and 60 SCLC patients) by setting up optimal biomarker joint models with a powerful computerized tool -gene expression programming (GEP). GEP is a learning algorithm that combines the advantages of genetic programming (GP) and genetic algorithms (GA). It specifically focuses on relationships between variables in sets of data and then builds models to explain these relationships, and has been successfully used in formula finding and function mining. As a basis for defining a GEP environment for SCLC and NSCLC prediction, three explicit predictive models were constructed. CEA and NSE are requentlyused lung cancer markers in clinical trials, CRP, LDH and Cyfra21-1 have significant meaning in lung cancer, basis on CEA and NSE we set up three GEP models-GEP 1(CEA, NSE, Cyfra21-1), GEP2 (CEA, NSE, LDH), GEP3 (CEA, NSE, CRP). The best classification result of GEP gained when CEA, NSE and Cyfra21-1 were combined: 128 of 135 subjects in the training set and 40 of 45 subjects in the test set were classified correctly, the accuracy rate is 94.8% in training set; on collection of samples for testing, the accuracy rate is 88.9%. With GEP2, the accuracy was significantly decreased by 1.5% and 6.6% in training set and test set, in GEP3 was 0.82% and 4.45% respectively. Serum Cyfra21-1 is a useful and sensitive serum biomarker in discriminating between NSCLC and SCLC. GEP modeling is a promising and excellent tool in diagnosis of lung cancer.

show abstract

“…HER2 has been reported to be overexpressed or amplified in a variety of human tumors (Nicholson et al, 2001;Rubin and Yarden, 2001;McAlpine et al, 2009;Ghaffari et al, 2011;Wang et al, 2011;Sardari et al, 2012;Duman et al, 2012;Panagiotou et al, 2012; RESEARCH ARTICLE Pazhoomand et al, 2013;Unal et al, 2013;Ziaian et al, 2014). The clinical significance of HER2 status in many tumor types is not yet clear except for breast, gastric, or gastroesophageal junction cancer patients (Nicholson et al, 2001;Gravalos and Jimeno, 2008;García-Velasco et al, 2008;Moatter et al, 2011;Wang et al, 2011;Duman et al, 2012;Pazhoomand et al, 2013;Tai et al, 2013;Unal et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

HER2 Expression in Ovarian Mucinous Carcinomas in Tunisia

Missaoui

Abdelkarim²,

Ayachi³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Ovarian mucinous carcinoma has a poor prognosis in advanced stages and a poor response to conventional chemotherapy. An efficient treatment is not yet available. We heere investigated HER2 expression and the potential for trastuzumab therapy in ovarian mucinous tumors. Materials and Methods: Immunohistochemistry was performed in formalin-fixed, paraffin-embedded tissue from 27 ovarian mucinous tumors including 14 carcinomas and 13 borderline tumors diagnosed in the Pathology Department, Farhet Hached Hospital, Sousse, between 1993 and 2013. The HercepTest (DAKO) was used for immunohistochemistry. Results: HER2 expression was observed in only one borderline tumor (7.7%) and in 14.3% of mucinous carcinomas of the ovary. Conclusions: Our results suggest that trastuzumab therapy would be an option for patients with mucinous carcinoma when the tumor has HER2 overexpression.

show abstract

Association of High LDH and Low Glucose Levels in Pleural Space with HER2 Expression in Non-Small Cell Lung Cancer

Cited by 10 publications

References 18 publications

Lactic dehydrogenase and cancer an overview

Lactic dehydrogenase and cancer an overview

Prediction of Lung Cancer Based on Serum Biomarkers by Gene Expression Programming Methods

HER2 Expression in Ovarian Mucinous Carcinomas in Tunisia

Contact Info

Product

Resources

About